# Rhythm Pharmaceuticals, Inc.: overview

RYTM · Nasdaq · CIK 1649904 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rytm.md) · [Financials](/companies/rytm/financials.md) · [Filings](/companies/rytm/filings.md) · [Insiders](/companies/rytm/insiders.md)

Latest reported revenue: [$71.3m](/filings/0001628280-26-052533.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-052533).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [33.3](/filings/0001104659-25-106264.md) | [41.8 d](/filings/0001628280-26-012399.md) | [32.7](/filings/0001628280-26-030549.md) | [48.5](/filings/0001628280-26-052533.md) | [51.3](/filings/0001104659-25-106264.md) | [57.3 d](/filings/0001628280-26-012399.md) | [60.1](/filings/0001628280-26-030549.md) | [71.3](/filings/0001628280-26-052533.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(132.0%)](/filings/0001104659-25-106264.md) | [(98.6%) d](/filings/0001628280-26-012399.md) | [(143.7%)](/filings/0001628280-26-030549.md) | [(93.4%)](/filings/0001628280-26-052533.md) | [(102.6%)](/filings/0001104659-25-106264.md) | [(82.2%) d](/filings/0001628280-26-012399.md) | [(87.1%)](/filings/0001628280-26-030549.md) | [(68.1%)](/filings/0001628280-26-052533.md) |
| Net margin | % | [(131.2%)](/filings/0001104659-25-106264.md) | [(103.5%) d](/filings/0001628280-26-012399.md) | [(151.4%)](/filings/0001628280-26-052533.md) | [(96.1%)](/filings/0001628280-26-052533.md) | [(103.1%)](/filings/0001104659-25-106264.md) | [(83.0%) d](/filings/0001628280-26-012399.md) | [(92.6%)](/filings/0001628280-26-052533.md) | [(69.2%)](/filings/0001628280-26-052533.md) |
| Diluted EPS | $ per share | [(0.73)](/filings/0001104659-25-106264.md) | not reported | [(0.81)](/filings/0001628280-26-030549.md) | [(0.75)](/filings/0001628280-26-052533.md) | [(0.82)](/filings/0001104659-25-106264.md) | not reported | [(0.83)](/filings/0001628280-26-030549.md) | [(0.73)](/filings/0001628280-26-052533.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.2](/filings/0001558370-24-002181.md) | [23.6](/filings/0001558370-25-001889.md) | [77.4](/filings/0001628280-26-012399.md) | [130](/filings/0001628280-26-012399.md) | [190](/filings/0001628280-26-012399.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(5391.9%)](/filings/0001558370-24-002181.md) | [(757.9%)](/filings/0001558370-25-001889.md) | [(238.1%)](/filings/0001628280-26-012399.md) | [(204.0%)](/filings/0001628280-26-012399.md) | [(101.2%)](/filings/0001628280-26-012399.md) |
| Net margin | % | [(2207.1%)](/filings/0001558370-24-002181.md) | [(766.2%)](/filings/0001558370-25-001889.md) | [(238.5%)](/filings/0001628280-26-012399.md) | [(200.3%)](/filings/0001628280-26-012399.md) | [(103.6%)](/filings/0001628280-26-012399.md) |
| Diluted EPS | $ per share | [(1.40)](/filings/0001558370-24-002181.md) | [(3.47)](/filings/0001558370-24-002181.md) | [(3.20)](/filings/0001628280-26-012399.md) | [(4.34)](/filings/0001628280-26-012399.md) | [(3.11)](/filings/0001628280-26-012399.md) |
| Free cash flow | $m | [(146)](/filings/0001558370-24-002181.md) | [(174)](/filings/0001558370-25-001889.md) | [(136)](/filings/0001628280-26-012399.md) | [(114)](/filings/0001628280-26-012399.md) | [(117)](/filings/0001628280-26-012399.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rytm/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $740.2m | 6,666,837 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $683.6m | 6,156,902 |  | Reduced −80,249 |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $622.3m | 5,604,483 |  | Unchanged |
| [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $351.8m | 3,168,853 |  | Reduced −248,656 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $348.3m | 3,136,895 |  | Added +96,177 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $333.8m | 3,005,977 |  | Added +38,152 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $292.2m | 2,652,746 |  | Added +1,099,102 |
| [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $287.2m | 2,586,295 |  | Added +212,500 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $285.7m | 2,573,529 |  | Added +301,678 |
| [WESTFIELD CAPITAL MANAGEMENT CO LP](/funds/1177719.md) | 2026-06-30 | $245.2m | 2,208,595 |  | Added +279,472 |

## Recent filings

[All 816 filings](/companies/rytm/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-04 | 20:05 ET | [10-Q](/filings/0001628280-26-052533.md) | Quarterly report, period 2026-06-30 | 0001628280-26-052533 |
| 2026-08-04 | 11:49 ET | [8-K](/filings/0001628280-26-052170.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-052170 |
| 2026-06-25 | 20:46 ET | [8-K](/filings/0001628280-26-045569.md) | 5.07 Shareholder vote results | 0001628280-26-045569 |
| 2026-06-15 | 20:07 ET | [8-K](/filings/0001628280-26-043170.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-043170 |
| 2026-05-05 | 20:15 ET | [10-Q](/filings/0001628280-26-030549.md) | Quarterly report, period 2026-03-31 | 0001628280-26-030549 |
| 2026-05-05 | 11:48 ET | [8-K](/filings/0001628280-26-030136.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-030136 |
| 2026-04-29 | 20:09 ET | [DEF 14A](/filings/0001628280-26-028375.md) | Proxy statement, period 2026-06-24 | 0001628280-26-028375 |
| 2026-04-03 | 19:06 ET | [8-K](/filings/0001628280-26-023606.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-023606 |
| 2026-03-26 | 20:06 ET | [8-K](/filings/0001628280-26-021414.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-021414 |
| 2026-03-20 | 13:20 ET | [8-K](/filings/0001628280-26-019995.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-019995 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-012399.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5a7db8c8-d3bd-4438-85ea-dbccba562c7d)

## About the filer

- CIK: 1649904
- Tickers: RYTM
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.